Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials

Journal of Psychopharmacology

Volumn 26, Issue 7, 2012, Pages 994-1002

  Krebs, Teri S ^a,b,c   Johansen, Pål ØRjan ^a,b,c  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b MCLEAN HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

alcohol related disorders; Alcoholism; hallucinogens; meta analysis; psychedelics; substance related disorders

Indexed keywords

DEXAMPHETAMINE; EPHEDRINE SULFATE; LYSERGIDE;

AGITATION; ALCOHOLISM; CLINICAL EFFECTIVENESS; CONFUSION; DRUG EFFICACY; DRUG RESPONSE; GRAND MAL SEIZURE; HUMAN; LOW DRUG DOSE; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; ALCOHOLISM; COMBINED MODALITY THERAPY; HALLUCINOGENS; HUMANS; LYSERGIC ACID DIETHYLAMIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SUBSTANCE ABUSE TREATMENT CENTERS;

EID: 84861475536     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112439253     Document Type: Review

References (39)

1. Ables MF, Eng EW. Group treatment of chronic alcoholism with LSD-25.; 1967; 1967.
2. Ables MF, Eng EW, Curtin ME. Group treatment of chronic alcoholism with LSD-25: study II. Newsletter for research in psychology, United States Veterans Administration. 1970; 12: 17-21
3. Albaugh BJ, Anderson PO. Peyote in the treatment of alcoholism among American Indians. Am J Psychiatry. 1974; 131: 1247-1250
4. Diagnostic and Statistical Manual for Mental Disorders. 1952 ) Diagnostic and Statistical Manual for Mental Disorders. First Edition. Washington, DC: American Psychiatric Association, 39. Washington, DC: American Psychiatric Association; 1952: 39.
5. Bowen WT, Soskin RA, Chotlos JW. Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study. J Nerv Ment Dis. 1970; 150: 111-118
6. Bruhn JG, De Smet PA, El-Seedi HR, Beck O. Mescaline use for 5700 years. Lancet. 2002; 359: 1866
7. Denson R, Sydiaha D. A controlled study of LSD treatment in alcoholism and neurosis. Br J Psychiatry. 1970; 116: 443-445
8. Ditman KS, Moss T, Forgy E, et al. Characteristics of alcoholics volunteering for lysergide treatment. Q J Stud Alcohol. 1970; 31: 414-422
9. Dyck E Psychedelic Psychiatry: LSD from Clinic to Campus. Baltimore, MD: Johns Hopkins University Press; 2008 :
10. Fábregas JM, González D, Fondevila S, et al. Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend. 2010; 111: 257-261
11. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006; 187: 268-283 (Pubitemid 44088380)
12. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011; 68: 71-78
13. Henderson LH, Glass WJ LSD: Still With Us After All These Years. New York: Lexington Books; 1994 :
14. HigginsJPTAltmanDG (2008) Chapter 8: Assessing risk of bias in included studies. In: HigginsJPTGreenS (eds) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1 (updated September 2008). Cochrane Collaboration. Available at: http://www.cochrane-handbook.org
15. Hollister LE, Shelton J, Krieger G. A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics. Am J Psychiatry. 1969; 125: 1352-1357
16. Jensen SE. A treatment program for alcoholics in a mental hospital. Q J Stud Alcohol. 1962; 23: 315-320
17. Jensen SE. Treatment of chronic alcoholism with lysergic acid diethylamide. Can Psychiatr Assoc J. 1963; 8: 182-188
18. Johnson FG. LSD in the treatment of alcoholism. Am J Psychiatry. 1969; 126: 481-487
19. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008; 22: 603-620
20. Krampe H, Ehrenreich H. Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr Pharm Des. 2010; 16: 2076-2090
21. Kurland AA, Savage C, Pahnke WN, Grof S, Olsson JE. LSD in the treatment of alcoholism. Advances in neuropsychopharmacology: proceedings of the 7th congress of the collegium internationale neuro-psychopharmacologicum; 1971 Amsterdam: North-Holland; 1971. 361.
22. Ludwig AM, Levine J, Stark L, Lazar R. A clinical study of LSD treatment in alcoholism. Am J Psychiatry. 1969; 126: 59-69
23. Ludwig AM, Levine J, Stark LH LSD and alcoholism: a clinical study of treatment efficacy. Springfield, IL: Charles C Thomas; 1970 :
24. Mangini M. Treatment of alcoholism using psychedelic drugs: a review of the program of research. J Psychoactive Drugs. 1998; 30: 381-418 (Pubitemid 29046930)
25. McGlothlinWH (1964) Hallucinogenic Drugs: A Perspective with Special Reference to Peyote and Cannabis. Santa Monica, CA: RAND Corporation. Available at: http://www.rand.org/pubs/papers/P2937.html (accessed 25 February 2012).
26. Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010; 376: 1558-1565
27. Osmond H, Albahary R, Cheek F, Sarett M The use of LSD in psychotherapy and alcoholism. Abramson HA, ed. Indianapolis, IN: Bobbs-Merrill; 1967: 434-457.
28. Pahnke WN, Kurland AA, Unger S, Savage C, Grof S. The experimental use of psychedelic (LSD) psychotherapy. JAMA. 1970; 212: 1856-1863
29. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008; 14: 295-314
30. Rehm J, Mathers C, Popova S, et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009; 373: 2223-2233
31. Rösner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010a; 9: CD004332
32. Rösner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010b; 12: CD001867
33. Savage C, McCabe OL. Residential psychedelic (LSD) therapy for the narcotic addict. Arch Gen Psychiatry. 1973; 28: 808-814
34. Schuckit MA. Alcohol-use disorders. Lancet. 2009; 373: 492-501
35. Smart RG, Storm T, Baker EF, Solursh L. A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior. Q J Stud Alcohol. 1966; 27: 469-482
36. Smart RG, Storm T, Baker EF, Solursh L Lysergic acid diethylamide (LSD) in the treatment of alcoholism; an investigation of its effects on drinking behavior, personality structure, and social functioning. Toronto: Published for the Alcoholism and Drug Addiction Research Foundation of Ontario: University of Toronto Press; 1967 :
37. Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 2011; 25: 4135-4152
38. Q J Stud Alcohol. Tomsovic M Edwards RV, ed. 1970: 932-949.
39. Van Dusen W, Wilson W, Miners W, Hook H. Treatment of alcoholism with lysergide. Q J Stud Alcohol. 1967; 28: 295-304